Mylan, U.S. Finalize $465 Million EpiPen Settlement

Mylan has finalized a $465 million settlement with the U.S. Justice Department, Reuters reported on Thursday. The company was accused of overcharging the government for EpiPen emergency allergy treatment, as well as misclassifying the medicine to avoid paying Medicaid rebates. “Taxpayers rightly expect companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules,” said Acting U.S. Attorney William Weinreb, in a statement. Mylan admitted wrongdoing when entering the settlement. Chief Executive Heather Bresch said, “Bringing closure to this matter is the right course of action for Mylan and our stakeholders to allow us to move forward.”